Azido flufenamiko

Azido flufenamiko
Formula kimikoa	C14H10F3NO2
SMILES kanonikoa	2D eredua
MolView	3D eredua
Mota	konposatu kimiko
Ezaugarriak
Fusio-puntua	134 °C
Masa molekularra	281,066 Da
Erabilera
Elkarrekintza	Anoctamin 1 (en) , Gap junction protein beta 7 (en) , Gap junction protein beta 2 (en) , gap junction protein beta 6 (en) , Gap junction protein gamma 3 (en) , Gap junction protein beta 4 (en) , Gap junction protein beta 3 (en) , Gap junction protein beta 5 (en) , Gap junction protein delta 3 (en) , Gap junction protein beta 1 (en) , Gap junction protein delta 2 (en) , Gap junction protein alpha 4 (en) , Gap junction protein alpha 5 (en) , Gap junction protein delta 4 (en) , Gap junction protein alpha 1 (en) , Gap junction protein gamma 1 (en) , Gap junction protein alpha 3 (en) , Gap junction protein gamma 2 (en) , Gap junction protein alpha 8 (en) , Gap junction protein alpha 9 (en) , Gap junction protein alpha 10 (en) , Pannexin 1 (en) , Pannexin 2 (en) , Pannexin 3 (en) , Transient receptor potential cation channel subfamily C member 5 (en) , Transient receptor potential cation channel subfamily M member 2 (en) , Transient receptor potential cation channel, subfamily M, member 4 (en) , Transient receptor potential cation channel subfamily M member 5 (en) eta Polycystin 2 like 1, transient receptor potential cation channel (en)
Rola	antiinflamatorio
Identifikatzaileak
InChlKey	LPEPZBJOKDYZAD-UHFFFAOYSA-N
CAS zenbakia	530-78-9
ChemSpider	3254
PubChem	3371
Reaxys	1996069
Gmelin	42638
ChEBI	1327188
ChEMBL	CHEMBL23588
EC zenbakia	208-494-1
ECHA	100.007.723
MeSH	D005439
RxNorm	4453
UNII	60GCX7Y6BH
KEGG	D01581
PDB Ligand	FLF

Ohar medikoa

Oharra: Wikipediak ez du mediku aholkurik ematen. Tratamendua behar duzula uste baduzu, jo ezazu sendagilearengana.

Azido flufenamikoa^[1] antiinflamatorio ez esteroideo familiako botika da. Azido fenamiko edo fenamatoaren deribatua,^[2] analgesiko eta antipiretikoa ere bada.

2020ko urrian, FDAk medikamentuaren etiketa hanturaren aurkako sendagai ez esteroide guztietarako eguneratzea eskatu zuen, jaiotzeagatiko giltzurrun-arazoen arriskua deskribatzeko, likido amniotikoaren maila baxuan gertatzen baitira.^[3]